Four lawmakers announced on March 7 that they had reintroduced the psychedelic therapy bill.Rep. Nancy Mace Senator Madeleine DeanSenators Cory Booker, and Senators Rand Paul, breakthrough therapyan updated bill amending the Controlled Substances Act (CSA) and opening access to substances such as MDMA and psilocybin for medical patients.
“Breakthrough therapies give us the opportunity to improve the lives of all those who suffer from treatment-resistant mental illness. It is our duty to make possible treatment options accessible.” Mace said in a press release“This law removes bureaucratic hurdles that have prevented important research and the compassionate use of potentially life-saving treatments.”
If you pass the bill will be amended The CSA’s definition of “currently approved medical use with severe restrictions” is “contains active ingredients of therapeutic agents that have received FDA breakthrough therapy designation or extended access approval.” In effect, this allows the Drug Enforcement Agency to move certain “breakthrough therapies” for Schedule I substances to the Schedule II category. The Schedule II category is less restrictive when it comes to research and research into medical compassionate use.
“Recent studies show that certain Schedule I substances, such as MDMA and psilocybin, may offer significant advances in the treatment of depression, severe post-traumatic stress disorder, and addiction. booker said“This bill would eliminate unfairly burdensome rules and regulations that slow or prevent researchers from studying these breakthrough mental health treatments, and would eliminate those who are eligible for urgent care.” providing access to these promising therapies for vulnerable patients.”
of New version of invoice A section has been included stating that substances moved from Schedule I to Schedule II may be moved back to Schedule I. Schedule I drugs according to subsection,” says the text. In that case, the Attorney General will act within 90 days after he receives the letter from the Director to issue an interim final rule.
Originally, Booker and Paul Earlier version of this bill Passed in November 2022, no progress has been made in the Senate. Earlier, Booker and Paul also said, “right to tryThe law was enacted in July 2022. “Unfortunately, federal bureaucrats continue to block patients from trying to use Schedule I drugs under Right to Try. I am proud to lead this bipartisan legislation with Senator Booker. The law will remove government interference and give doctors more resources to help their patients.”
The growing support for psychedelics as a drug also provides evidence that patients can benefit from psychedelics.More than 40 organizations are supporting the new bill, according to a press release from Mace. Veteran Mental Health Leadership Coalition, reason for hopeand American Special Operations SocietyAlso, the Australian government will change the schedule of MDMA and psilocybin on February 3, allowing doctors to prescribe these substances to patients suffering from post-traumatic stress disorder (PTSD) or treatment-resistant depression. It is also important to mention that we recently announced that
Many patients, especially veterans, may benefit from access to MDMA and psilocybin treatment. There are other efforts underway to boost research efforts on cannabis as a way to treat PTSD and chronic pain in veterans. Senate Bill 326or the VA Medicinal Cannabis Research Act, which requires the U.S. Department of Veterans Affairs (VA) to conduct research and report its findings to Congress on its therapeutic value.